Side-by-side · Research reference
RetatrutidevsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed10/41 cited
BFDA-ApprovedVerified15/53 cited
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Retatrutide
Semaglutide
Primary target
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Retatrutide
Semaglutide
Frequency
Once weekly
Once weekly, same day each week
Titration schedule
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Evidence basis
Phase 2 trial; Phase 3 ongoingJastreboff 2023
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration
Indefinite for chronic indication (presumed)
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
Investigational; not commercially available
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
Any time of day
Any time of day, with or without food
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
04Side Effects & Safety
Parameter
Retatrutide
Semaglutide
GI symptoms
Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023
Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021
Glucose handling
Glycemic improvement; rare hyperglycemia from glucagon component
—
Thyroid C-cell tumours
Class warning (presumed)
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Injection site reaction
—
Mild erythema, pruritus
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Absolute Contraindications
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Retatrutide
Semaglutide
1. Reconstitution
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate weekly.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Once weekly, same day.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Refrigerate 2–8 °C. Light-protected.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
27–31G, 4–8 mm insulin syringe.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Retatrutide
— no documented stacks
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)